ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0988 • ACR Convergence 2023

    Elderly Patients’ Discontinuation of Biologic DMARDs in Patients with Rheumatic Diseases: Data from the Mexican Adverse Events Registry (BIOBADAMEX)

    Vijaya Rivera Terán1, David Vega Morales2, Miguel Angel Saavedra Salinas3, Daniel Xavier Xibillé Friedman4, Iris Colunga5, Sandra Carrillo Vazquez6, Dafhne Miranda Hernández7, Sergio Durán Barragán8, Erick Adrián Zamora Tehozol9, Angel Alejandro Castillo Ortiz10, Sandra Sicsik Ayala11, Fedra Irazoque Palazuelos6, Julio César Casasola Vargas12, Angelica Peña13, Omar Eloy Muñoz Monroy14, Azucena Ramos Sánchez2, Luis Valdés Corona15, Javier Merayo-Chalico16, Estefania Torres Valdez13, Aleni Paz Viscarra15 and Deshiré Alpízar Rodríguez1, 1Colegio Mexicano de Reumatología, Mexico City, Mexico, 2Instituto Mexicano del Seguro Social, Monterrey, Mexico, 3IMSS, Mexico City, Mexico, 4Práctica Privada, Cuernavaca, Mexico, 5Hospital Universitario UANL, Monterrey, Mexico, 6Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City, Mexico, 7Instituto Mexicano del Seguro Social, Mexico City, Mexico, 8Consulta Privada, Guadalajara, Mexico, 9Centro Médico Pensiones, Mérida, Mexico, 10Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mérida, Mexico, 11Instituto Mexicano del Seguro Social, Torreón, Mexico, 12Instituto de Seguridad Social del Estado de México y Municipios, Mexico City, Mexico, 13Instituto Mexicano del Seguro Social, Querétaro, Mexico, 14Hospital Central Militar, Mexico City, Mexico, 15Práctica Privada, Mexico City, Mexico, 16Reumátika, Centro de Vanguardia en Reumatología de la Ciudad de México, Mexico City, Mexico

    Background/Purpose: The approach to elderly patients (≥60 years) with rheumatic diseases offers certain difficulties and uncertainties. Older adults are a particularly vulnerable group who often…
  • Abstract Number: 1794 • ACR Convergence 2023

    The Role of the Deubiquitinase ZRANB1/TRABID in Inflammation and Bone Formation in Spondyloarthritis

    Archita Srinath1, Daniele Mauro2, Francesco Ciccia3 and Nigil Haroon4, 1University of Toronto, Toronto, ON, Canada, 2University of Campania, Naples, Italy, 3University of Campania - Luigi Vanvitelli, Naples, Italy, 4University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada

    Background/Purpose: Inflammation and new bone formation are important disease mediators in ankylosing spondylitis (AS). Recent studies in mice show that the deubiquitinase molecule TRABID epigenetically…
  • Abstract Number: 1693 • ACR Convergence 2023

    Blood Immunophenotyping Distinguishes Three Subgroups of Lupus Nephritis Patients with Distinct Kidney Infiltrates and Interferon Signatures

    Alice Horisberger1, Alec Griffith1, Arnon Arazi2, Joshua Keegan1, Kaitlyn Howard1, Takanori Sasaki1, Tusharkanti Ghosh3, Andrea Fava4, Jun Inamo5, John Pulford1, Ekaterina Murzin1, Brandon Hancock1, Katie Preisinger6, Maria Gutierrez-Arcelus7, Thomas Eisenhaure8, Joel Guthridge9, Paul Hoover10, Maria Dall'Era11, David Wofsy11, Diane L. Kamen12, Kenneth Kalunian13, Richard Furie14, H Michael Belmont15, Peter Izmirly6, Robert Clancy16, David Hildeman17, steve Woodle17, William Apruzzese18, Maureen McMahon19, Jennifer Grossman20, Jennifer Barnas21, Fernanda Payan-Schober22, Mariko Ishimori23, Accelerating Medicines Partnership Program RA SLE Network23, Matthias Kretzler24, Celine Berthier24, Jeff Hodgin24, Dawit Demeke24, Chaim Putterman25, Nir Hacohen8, Michael Brenner1, Jennifer Anolik21, Anne Davidson26, Judith James9, Soumya Raychaudhuri10, Michelle Petri27, Jill Buyon16, Betty Diamond26, The Accelerating Medicines Partnership In RA/SLE28, Fan Zhang29, James Lederer1 and Deepak Rao10, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Broad Institute of MIT and Harvard, Melrose, MA, 3School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, CO, 4Johns Hopkins University, Baltimore, MD, 5University of Colorado School of Medicine, Aurora, CO, 6New York University School of Medicine, New York, NY, 7Boston Children's Hospital, Boston, MA, 8Broad Institute of MIT and Harvard, Cambridge, MA, 9Oklahoma Medical Research Foundation, Oklahoma City, OK, 10Brigham and Women's Hospital, Boston, MA, 11University of California San Francisco, San Francisco, CA, 12Medical University of South Carolina, Charleston, SC, 13University of California San Diego, La Jolla, CA, 14Northwell Health, Manhasset, NY, 15NYU School of Medicine, New York, NY, 16NYU Grossman School of Medicine, New York, NY, 17University of Cincinnati College of Medicine, Cincinnati, OH, 18Accelerating Medicines Partnership® Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Network, Boston, MA, 19UCLA David Geffen School of Medicine, Los Angeles, CA, 20University of California Los Angeles, Los Angeles, CA, 21University of Rochester Medical Center, Rochester, NY, 22Texas Tech University Health Sciences Center, El Paso, TX, 23Cedars-Sinai Medical Center, Los Angeles, CA, 24University of Michigan, Ann Arbor, MI, 25Albert Einstein College of Medicine, Bronx, NY, 26Feinstein Institutes for Medical Research, Manhasset, NY, 27Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 28multisites, multisites, 29University of Colorado, Aurora, CO

    Background/Purpose: Patients with lupus nephritis (LN) have variable responses to standard-of-care therapy, and a third of patients with class III, IV, or V show a…
  • Abstract Number: 1761 • ACR Convergence 2023

    JAK/STAT Inhibition Modifies the Innate Lymphoid Cells 1 Immune Response in Patients with Rheumatoid Arthritis

    Lidia La Barbera1, Marianna Lo Pizzo1, Chiara Rizzo1, Leila Mohammadnezhad1, federica Camarda1, Francesco Ciccia2 and Giuliana Guggino1, 1University of Palermo, Palermo, Italy, 2University of Campania - Luigi Vanvitelli, Naples, Italy

    Background/Purpose: Recent evidence suggests that innate lymphoid cells (ILCs) might be involved in rheumatoid arthritis (RA) pathogenesis and individuals at risk of RA exhibited an…
  • Abstract Number: 1807 • ACR Convergence 2023

    Hypothyroidism Impacts Clinical and Healthcare Utilization Outcomes After Primary Total Hip Arthroplasty

    Sumanth Chandrupatla1, Kranti Rumalla2 and Jasvinder Singh1, 1University of Alabama at Birmingham, Birmingham, AL, 2Northwestern School of Medicine, Chicago, IL

    Background/Purpose: Most data on the effect of comorbidities on primary total hip arthroplasty (THA) outcomes is focused on conditions that directly impact joint health, or…
  • Abstract Number: 1571 • ACR Convergence 2023

    Tocilizumab in Pregnant Takayasu Arteritis – The Use of Tocilizumab at Conception and Throughout Pregnancy in Those with Takayasu Arteritis

    Nurul Aulia Zakaria1, Andrew Porter2, Robert Maughan2, Charis Pericleous2, Japna Satara3, Matthew Colquhoun4, Priyanka Agrawal3, jan Nouza3, Harold Wilson-Morkeh3, Taryn Youngstein2 and Justin Mason2, 1National Heart & Lung Institute, Imperial College London, Kuantan, Malaysia, 2National Heart & Lung Institute, Imperial College London, London, United Kingdom, 3Rheumatology, Hammersmith Hospital, London, United Kingdom, 4Department of Rheumatology, Imperial College Healthcare Trust, London, United Kingdom

    Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis predominantly affecting female of reproductive age. Tocilizumab (TCZ) is frequently used in synthetic DMARD refractory cases.…
  • Abstract Number: 0989 • ACR Convergence 2023

    Rheumatoid Arthritis and Risk of Migraine: A Population-based Nationally Representative Cohort

    Hyungjin Kim1, Seonyoung Kang2, Kyungdo Han3, Jinhyoung Jung4, Yeonghee Eun5, Eun-Mi Koh6, Jinseok kim7, Kwangmo Yang8, Hoon-Suk Cha2, Seulkee Lee2, Jaejoon Lee2 and Dong Wook Shin9, 1Department of Medical Humanities, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 3Department of Statistics and Actuarial Science, Soongsil University, Seoul, South Korea, 4Department of Medical statistics, College of Medicine, Catholic University of Korea, Seoul, South Korea, 5Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, 6Health Insurance Review and Assessment Service, Seoul, South Korea, 7Division of Rheumatology, Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, South Korea, 8Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 9Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Background/Purpose: Migraine is the second most prevalent neurologic disorder and is known to be associated with neurogenic inflammation. Previous studies suggest an association between migraine…
  • Abstract Number: 0990 • ACR Convergence 2023

    Association of Treatment and Disease Activity with Antibiotic Use and Hospitalized Infection Among People Living with Rheumatoid Arthritis: Baseline Data from a Longitudinal Study in the ArthritisPower Registry

    Kelly Gavigan1, Esteban Rivera2, Odette Kolenky3, Cassie Clinton4, Emily Holladay4, David Curtis5, Laura Stradford6, Jeffrey Curtis4, W. Benjamin Nowell6, Christian Curtis7 and Michael George8, 1Global Healthy Living Foundation, Upper Nyack, NY, 2Global Healthy Living Foundation, Long Island City, NY, 3Hospital of the University of Pennsylvania, Philadelphia, PA, 4University of Alabama at Birmingham, Birmingham, AL, 5Global Healthy Living Foundation, San Francisco, CA, 6Global Healthy Living Foundation, Nyack, NY, 7Illumination Health, Birmingham, AL, 8University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Infections are a major contributor to morbidity and mortality in patients (pts) with rheumatoid arthritis (RA). Little is known about the risk of non-serious…
  • Abstract Number: 1313 • ACR Convergence 2023

    Remotely Supervised Weight Loss and Exercise Training Improves Disease Activity and Patient Reported Outcomes in Older Patients with Rheumatoid Arthritis

    Brian Andonian, Leanna Ross, Alyssa Sudnick, Johanna Johnson, Carl Pieper, Connie Bales, Kathryn Porter Starr, William Kraus and Kim Huffman, Duke University, Durham, NC

    Background/Purpose: Older persons with rheumatoid arthritis (RA) are at increased risk for sarcopenic obesity, physical disability, adverse drug events, and cardiovascular disease; thus, there is…
  • Abstract Number: 1791 • ACR Convergence 2023

    Exploring the Mechanism of Anti-TNFα Therapy Non-response in Psoriatic Arthritis: The Role of TNF Receptor 2 Polymorphisms rs1061622

    James Sullivan1, Vandana Rai2, Jennifer Harvey2, Vincent Del Signore2, Unnikrishnan Chandrasekharan2 and M. Elaine Husni3, 1Cleveland Clinic Lerner College of Medicine, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH, 3Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH

    Background/Purpose: Despite the widespread use of anti-TNFα therapy in psoriatic arthritis (PsA), a significant proportion of patients fail to achieve a complete treatment response. There…
  • Abstract Number: 1690 • ACR Convergence 2023

    Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients with Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study

    Mikkel Østergaard1, Walter P. Maksymowych2, Mikael Boesen3, Robert Lambert4, Guillermo Valenzuela5, Michael Bubb6, Olga Kubassova7, Jyotsna Reddy8, Stephen Colgan9, Yuri Klyachkin10, Cynthia Deignan11, Lihua Tang8, Maria Paris8 and Philip J. Mease12, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, 2University of Alberta, Edmonton, AB, Canada, 3Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Naerum, Denmark, 4Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, 5Integral Rheumatology & Immunology Specialists, Plantation, FL, 6University of Florida, Gainesville, FL, 7Image Analysis Group, Philadelphia, PA, 8Amgen, Inc., Thousand Oaks, CA, 9Amgen, Inc., Halton Hills, ON, Canada, 10Amgen, Inc., Lexington, KY, 11Amgen, Inc., Agoura Hills, CA, 12Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA

    Background/Purpose: PsA is characterized by inflammatory arthritis, enthesitis, dactylitis, and spondylitis. Apremilast (APR) is an oral immunomodulating phosphodiesterase-4 inhibitor approved for the treatment of PsA.…
  • Abstract Number: 1811 • ACR Convergence 2023

    Strong Relationships Between Body Component Changes and Serum Uric Acid Variability

    Jiwon Hwang1, Mi Yeon Lee2, Yeonghee Eun3 and Joong Kyong Ahn3, 1Division of Rheumatology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon-si, South Korea, 2Division of Biostatistics, Department of R&D Management, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Background/Purpose: Obesity has a well-known relationship with higher serum uric acid (SUA) levels. Skeletal muscles are another site for producing uric acid as the endogenous…
  • Abstract Number: 1763 • ACR Convergence 2023

    Asthma Severity Is Associated Increased Serum Anti-cyclic Antibody Level at Baseline and in Increase During Longitudinal Follow-up

    Drayton Rorah1, Linh Ngo2, Mario Castro2, Kristen Demoruelle3 and Scott Matson4, 1University of Kansas Medical Center, Kansas City, KS, 2University of Kansas School of Medicine, Kansas City, KS, 3University of Colorado Anschutz Medical Campus, Aurora, CO, 4University of Kansas School of Medicine, Kansas City, MO

    Background/Purpose: The lung airways have been implicated in the pathogenesis of RA. RA-associated autoantibodies, including anti-cyclic citrullinated peptide (anti-CCP) antibodies are found to be generated…
  • Abstract Number: 1699 • ACR Convergence 2023

    Immunosuppression with Targeted Therapies Reduces Morbidity and Mortality in Pre-Capillary Pulmonary Hypertension Associated with Systemic Sclerosis: A EUSTAR Analysis

    Cosimo Bruni1, Havard Fretheim2, Lorenzo Tofani3, Yannick Weber1, Eric Hachulla4, Patricia Carreira5, Dilia Giuggioli6, Paolo Airò7, Elise Siegert8, Ulf Müller-Ladner9, marco Matucci Cerinic10, Gabriela Riemekasten11, Carmen Pilar Simeon-Aznar12, Jeska de Vries-Bouwstra13, Lesley Ann Saketkoo14, Joerg Distler15, Alexandra Balbir-Gurman16, Ivan Castellvi17, Elisabetta Zanatta18, Vanessa Smith19, Christopher Denton20, Britta Maurer21, Alessandro Giollo18, Florenzo Iannone22, Lorenzo Dagna23, Marie-Elise Truchetet24, Masataka Kuwana25, Yannick ALLANORE26, Yoshiya Tanaka27, Mickael Martin28, Edoardo Rosato29, Ana Maria Gheorghiu30, Francesco Del Galdo31, Kamal Solanki32, Alessandra Vacca33, CATARINA RESENDE34, SUSANA VIEIRA35, Laszlo Czirjak36, Marko Barisic37, Francesco Paolo Cantatore38, valeria Riccieri39, Kristofer Andréasson40, Lorinda Chung41, Carolina Muller42, Daniela OPRIS-BELINSKI43, Simona Rednic44, Petros Sfikakis45, Yair Levy46, Anna Maria Hoffmann-Vold47, Oliver Distler1, Vivien Hsu48, Stefan Heitmann49, Gianluca Moroncini50, Michele Iudici51, Joerg Henes52, Ellen De Langhe53, Ariane Herrick54 and Carlomaurizio Montecucco55, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2Oslo University Hospital, Oslo, Norway, 3Department of Statistics, Computer Science, Applications, University of Florence, Florence, Italy, 4University of Lille, Lille, France, 5Hospital Universitario 12 de Octubre, Madrid, Spain, 6Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, 7Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, 8Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, 9Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, 10Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, 11University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, 12Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitario Vall d'Hebronh, Barcelona, Spain, 13Leiden University Medical Center, Leiden, Netherlands, 14University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, 15Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, 16Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, 17Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, 18Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, 19Ghent University Hospital, Gent, Belgium, 20University College London, London, United Kingdom, 21University Hospital Bern, University Bern, Bern, Switzerland, 22Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, 23Ospedale San Raffaele, Milano, Italy, 24Bordeaux University Hospital, Bordeaux, France, 25Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 26Université Paris Cité, Paris, France, 27University of Occupational and Environmental Health, Kitakyushu, Japan, 28Department of Internal Medicine, INSERM U1313, Poitiers University, Poitiers University Hospital, Poitiers, France, 29Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy, 30Department of Internal Medicine and Rheumatology, Ion Cantacuzino Clinical Hospital, Bucharest, Romania, 31University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, 32Department of Rheumatology, Te Whatu Ora Health New Zealand Waikato, Hamilton, New Zealand, 33II Chair of Rheumatology, University of Cagliari-Policlinico Universitario, Monserrato, Italy, 34Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Lisboa, Portugal, 35Hospital Fernando Fonseca, Lisbon, Portugal, 36Dept. Rheumatol Immunol, Medical School, university of Pecs, Pecs, Hungary, 37Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia, 38Rheumatology Clinic – Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, 39Department of Clinical, Internal and Cardiovascular Specialities, Sapienza University of Rome, Roma, Italy, 40Lund University, Lund, Sweden, 41Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, 42Federal University of Parana, CURITIBA / PR, Brazil, 43Saint Mary Hospital, Bucharest, Romania, 44Prof Dr Simona Rednic, Cluj, Romania, 45National Kapodistrian University of Athens Medical School, Athens, Greece, 46Meir Medical Center, Autoimmune Research Laboratory, Kfar-Saba, Israel, 47Oslo University Hospital, Department of Rheumatology, Oslo, Norway, 48Rutgers-RWJ Medical School, South Plainfield, NJ, 49Department of Rheumatology, Marienhospital Stuttgart, Böheimstrasse 37, D-70199, Stuttgart, Germany, 50Marche Polytechnic University, Ancona, Italy, 51Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Geneva, Switzerland, 52University Hospital Tuebingen, Tuebingen, Germany, 53Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium, 54University of Manchester, Salford, United Kingdom, 55Unità Operativa e Cattedra di Reumatologia, IRCCS Policlinico S Matteo, Pavia, Italy

    Background/Purpose: Systemic sclerosis (SSc) associated pre-capillary pulmonary hypertension (precapPH) is a severe condition that requires prompt treatment. Although immunosuppressants (IMS) are standard of care for…
  • Abstract Number: 1573 • ACR Convergence 2023

    Inpatient Prevalence and Comorbidity of Takayasu’s Arteritis: Nationwide Inpatient Sample 2016-2020

    Husam el Sharu1, Sukhvir Singh1, Omar Alwahadneh2, Mohammad Alqaisieh3 and Laksmi Subramanian1, 1East Carolina University, Greenville, NC, 2Carle Foundation Hospital, Urbana, IL, 3Hamilton Medical Center, Dalton, GA

    Background/Purpose: Takayasu’s Arteritis (TAK) is a granulomatous large-vessel vasculitis that affects the aorta and its branches, and it is more commonly observed in women. We…
  • « Previous Page
  • 1
  • …
  • 282
  • 283
  • 284
  • 285
  • 286
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology